Tianqi Xu

School of Basic Medicine

H指数:13

被引数:420

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Folic acid alleviates neuroinflammation after intracerebral hemorrhage by epigenetically regulating the AMPD2/DCK/NF-κB pathway

叶酸通过表观遗传调控AMPD2/DCK/NF-κB通路减轻脑出血后的神经炎症

Phytomedicine

IF8.3

2026-08-010

PRE

Fingolimod overcomes cisplatin resistance in esophageal squamous cell carcinoma by targeting NUP54 to disrupt homologous recombination repair

fingolimod通过靶向NUP54破坏同源重组修复克服食管鳞状细胞癌的顺铂耐药性

Cell Communication and Signaling

IF8.9

2026-08-010

Imaging of ROR1 expression in tumors using radiolabeled affibody molecules

使用放射性标记的亲和体分子对肿瘤中ROR1表达进行成像

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2026-08-010

[161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma

[161Tb]Tb-DOTATATE作为神经母细胞瘤的潜在治疗选择

EJNMMI Research

IF3

2026-07-280

Synthetic lethality in cancer: mechanism exploration and therapeutic applications

癌症中的合成致死性：机制探索与治疗应用

Cell Communication and Signaling

IF8.9

2026-05-070

OAAI

Probiotic potential of Bacillus velezensis MZ-09: Assessing characteristics and safety through in vitro and in vivo analyses

枯草芽孢杆菌Bacillus velezensis MZ-09的益生菌潜力：通过体外和体内分析评估其特性和安全性

Microbiological Research

IF6.9

2025-08-200

PRE

Development of a novel nanobody-fused flagellin adjuvant to enhance immunogenicity in a PCV2 subunit vaccine

开发一种新型纳米抗体融合菌毛蛋白佐剂以增强PCV2亚单位疫苗的免疫原性

Microbial Pathogenesis

IF3.5

2025-07-150

PRE

Reduction of renal activity retention of radiolabeled albumin binding domain-derived affinity proteins using a non-residualizing label strategy compared with a cleavable glycine-leucine-glycine-lysine-linker

MOLECULAR MEDICINE REPORTS

IF3.5

2023-12-280

OAAI

Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3

NUCLEAR MEDICINE AND BIOLOGY

IF3

2023-09-014

OAAI

Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

PHARMACEUTICS

IF5.5

2022-08-2510

OAAI

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

PHARMACEUTICS

IF5.5

2022-08-024

OAAI

Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT

PHARMACEUTICS

IF5.5

2022-07-157

OAAI

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071

PHARMACEUTICS

IF5.5

2022-05-208

OAAI

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

ONCOLOGY REPORTS

IF3.9

2022-03-185

OAAI

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

PHARMACEUTICS

IF5.5

2022-02-264

OAAI

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

PHARMACEUTICS

IF5.5

2021-11-2110

OAAI

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein

PHARMACEUTICS

IF5.5

2021-11-036

OAAI

Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-10-2810

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(R) Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain

PHARMACEUTICS

IF5.5

2021-06-0712

OAAI

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution

PHARMACEUTICS

IF5.5

2021-03-2312

OAAI

Tianqi Xu

个人简介

教育背景

工作经历

荣誉奖项

研究方向